Skip to main content
Erschienen in: Digestive Diseases and Sciences 9/2017

20.06.2017 | Original Article

Comparative Evaluation of Preliminary Screening Methods for Colorectal Cancer in a Mass Program

verfasst von: Ding Ye, Qiuchi Huang, Qilong Li, Xiyi Jiang, Mayila Mamat, Mengling Tang, Jianbing Wang, Kun Chen

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The fecal immunochemical test (FIT) has been widely used in preliminary screening for colorectal cancer (CRC). The high-risk factor questionnaire (HRFQ) and quantitative risk-assessment method (QRAM) are recommended for estimating the risk of CRC qualitatively and quantitatively in China.

Aim

We aimed to prospectively compare the diagnostic values of CRC preliminary screening methods to identify which method is preferable as a screening strategy.

Methods

Individuals aged 40–74 years old were enrolled in a mass CRC screening program from January 1, 2007 to December 31, 2014, in Jiashan County, Zhejiang Province, China. FIT of two stool specimens at 1-week intervals was performed by laboratory personnel and face-to-face interviews were conducted by trained investigators. Screening data in the program were linked to a CRC surveillance and registry system, and CRC cases reported in the system were regarded as true patients.

Results

A total of 96,043 subjects were included. The sensitivity and specificity of FIT for detecting CRC cases were 75.49% (95% CI 69.84–80.39) and 90.36% (95% CI 90.17–90.54), respectively. QRAM was more sensitive (p < 0.001) and less specific (p < 0.001) than HRFQ. The sensitivity and specificity of FIT along with HRFQ were 86.56% (95% CI 81.81–90.22) and 81.37% (95% CI 81.12–81.62), and those of FIT along with QRAM were 88.93% (95% CI 84.47–92.23) and 73.95% (95% CI 73.67–74.23).

Conclusions

Our findings suggest that CRC preliminary screening with FIT and QRAM in parallel has high sensitivity and satisfactory specificity, and is a useful strategy in mass screening programs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. New Engl J Med. 1993;328:1365–1371.CrossRefPubMed Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. New Engl J Med. 1993;328:1365–1371.CrossRefPubMed
2.
Zurück zum Zitat Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.CrossRefPubMed Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.CrossRefPubMed
3.
Zurück zum Zitat Rabeneck L, Paszat LF, Saskin R, Stukel TA. Association between colonoscopy rates and colorectal cancer mortality. Am J Gastroenterol. 2010;105:1627–1632.CrossRefPubMed Rabeneck L, Paszat LF, Saskin R, Stukel TA. Association between colonoscopy rates and colorectal cancer mortality. Am J Gastroenterol. 2010;105:1627–1632.CrossRefPubMed
4.
Zurück zum Zitat Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–1633.CrossRefPubMed Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–1633.CrossRefPubMed
5.
Zurück zum Zitat Meester RG, Doubeni CA, Lansdorp-Vogelaar I, et al. Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol. 2015;25:208–213.CrossRefPubMed Meester RG, Doubeni CA, Lansdorp-Vogelaar I, et al. Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol. 2015;25:208–213.CrossRefPubMed
6.
Zurück zum Zitat Bibbins-Domingo K, Grossman DC, Curry SJ, et al. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315:2564–2575.CrossRefPubMed Bibbins-Domingo K, Grossman DC, Curry SJ, et al. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315:2564–2575.CrossRefPubMed
7.
Zurück zum Zitat Segnan N, Patnick J, von Karsa L, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: European Commission, Publications Office of the European Union; 2010. Segnan N, Patnick J, von Karsa L, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: European Commission, Publications Office of the European Union; 2010.
8.
Zurück zum Zitat Provenzale D, Jasperson K, Ahnen DJ, et al. Colorectal cancer screening, version 1.2015. J Natl Compr Canc Netw. 2015;13:959–968.CrossRefPubMed Provenzale D, Jasperson K, Ahnen DJ, et al. Colorectal cancer screening, version 1.2015. J Natl Compr Canc Netw. 2015;13:959–968.CrossRefPubMed
9.
Zurück zum Zitat Sung JJ, Ng SC, Chan FK, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015;64:121–132.CrossRefPubMed Sung JJ, Ng SC, Chan FK, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015;64:121–132.CrossRefPubMed
10.
Zurück zum Zitat Arbyn M, Van Oyen H, Lynge E, Micksche M, Faivre J, Jordan J. European Commission’s proposal for a council recommendation on cancer screening. BMJ. 2003;327:289–290.CrossRefPubMedPubMedCentral Arbyn M, Van Oyen H, Lynge E, Micksche M, Faivre J, Jordan J. European Commission’s proposal for a council recommendation on cancer screening. BMJ. 2003;327:289–290.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124:544–560.CrossRefPubMed Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124:544–560.CrossRefPubMed
12.
Zurück zum Zitat Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test. Hemoccult BMJ. 1998;317:559–565.CrossRefPubMed Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test. Hemoccult BMJ. 1998;317:559–565.CrossRefPubMed
13.
Zurück zum Zitat Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol. 2008;103:1541–1549.CrossRefPubMed Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol. 2008;103:1541–1549.CrossRefPubMed
14.
Zurück zum Zitat Jessup JM, Menck HR, Fremgen A, Winchester DP. Diagnosing colorectal carcinoma: clinical and molecular approaches. CA Cancer J Clin. 1997;47:70–92.CrossRefPubMed Jessup JM, Menck HR, Fremgen A, Winchester DP. Diagnosing colorectal carcinoma: clinical and molecular approaches. CA Cancer J Clin. 1997;47:70–92.CrossRefPubMed
15.
Zurück zum Zitat Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428.CrossRefPubMed Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428.CrossRefPubMed
16.
Zurück zum Zitat Meng W, Cai SR, Zhou L, Dong Q, Zheng S, Zhang SZ. Performance value of high risk factors in colorectal cancer screening in China. World J Gastroenterol. 2009;15:6111–6116.CrossRefPubMedPubMedCentral Meng W, Cai SR, Zhou L, Dong Q, Zheng S, Zhang SZ. Performance value of high risk factors in colorectal cancer screening in China. World J Gastroenterol. 2009;15:6111–6116.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Huang W, Liu G, Zhang X, et al. Cost-effectiveness of colorectal cancer screening protocols in urban Chinese populations. PLoS ONE. 2014;9:e109150.CrossRefPubMedPubMedCentral Huang W, Liu G, Zhang X, et al. Cost-effectiveness of colorectal cancer screening protocols in urban Chinese populations. PLoS ONE. 2014;9:e109150.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Zheng S, Chen K, Liu XY, et al. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum. 2003;46:51–58.CrossRefPubMed Zheng S, Chen K, Liu XY, et al. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum. 2003;46:51–58.CrossRefPubMed
19.
Zurück zum Zitat Sarkar R, Dey S, Pal M, et al. Risk prediction for oral potentially malignant disorders using fuzzy analysis of cytomorphological and autofluorescence alterations in habitual smokers. Future Oncol. 2017;13:499–511.CrossRefPubMed Sarkar R, Dey S, Pal M, et al. Risk prediction for oral potentially malignant disorders using fuzzy analysis of cytomorphological and autofluorescence alterations in habitual smokers. Future Oncol. 2017;13:499–511.CrossRefPubMed
20.
Zurück zum Zitat Hu Y, Wang Z, Wen J, Li Y. Stochastic fuzzy environmental risk characterization of uncertainty and variability in risk assessments: a case study of polycyclic aromatic hydrocarbons in soil at a petroleum-contaminated site in China. J Hazard Mater. 2016;316:143–150.CrossRefPubMed Hu Y, Wang Z, Wen J, Li Y. Stochastic fuzzy environmental risk characterization of uncertainty and variability in risk assessments: a case study of polycyclic aromatic hydrocarbons in soil at a petroleum-contaminated site in China. J Hazard Mater. 2016;316:143–150.CrossRefPubMed
21.
Zurück zum Zitat Beheshti I, Olya HG, Demirel H. Risk assessment of Alzheimer’s disease using the information diffusion model from structural magnetic resonance imaging. J Alzheimers Dis. 2016;52:1335–1342.CrossRefPubMed Beheshti I, Olya HG, Demirel H. Risk assessment of Alzheimer’s disease using the information diffusion model from structural magnetic resonance imaging. J Alzheimers Dis. 2016;52:1335–1342.CrossRefPubMed
22.
Zurück zum Zitat Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637–1649.CrossRefPubMed Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637–1649.CrossRefPubMed
23.
Zurück zum Zitat Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–1595.CrossRefPubMed Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–1595.CrossRefPubMed
24.
Zurück zum Zitat Imperiale TF, Monahan PO, Stump TE, Glowinski EA, Ransohoff DF. Derivation and validation of a scoring system to stratify risk for advanced colorectal neoplasia in asymptomatic adults: a cross-sectional study. Ann Intern Med. 2015;163:339–346.CrossRefPubMedPubMedCentral Imperiale TF, Monahan PO, Stump TE, Glowinski EA, Ransohoff DF. Derivation and validation of a scoring system to stratify risk for advanced colorectal neoplasia in asymptomatic adults: a cross-sectional study. Ann Intern Med. 2015;163:339–346.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49:3049–3054.CrossRefPubMed Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49:3049–3054.CrossRefPubMed
26.
Zurück zum Zitat Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer I. 2007;99:1462–1470.CrossRef Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer I. 2007;99:1462–1470.CrossRef
27.
Zurück zum Zitat Launoy GD, Bertrand HJ, Berchi C, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer. 2005;115:493–496.CrossRefPubMed Launoy GD, Bertrand HJ, Berchi C, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer. 2005;115:493–496.CrossRefPubMed
28.
Zurück zum Zitat Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. a prospective, controlled, feasibility study. Int J Cancer. 2011;128:2415–2424.CrossRefPubMed Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. a prospective, controlled, feasibility study. Int J Cancer. 2011;128:2415–2424.CrossRefPubMed
29.
Zurück zum Zitat Chen CH, Wen CP, Tsai MK. Fecal immunochemical test for colorectal cancer from a prospective cohort with 513,283 individuals. Medicine. 2016;95:e4414.CrossRefPubMedPubMedCentral Chen CH, Wen CP, Tsai MK. Fecal immunochemical test for colorectal cancer from a prospective cohort with 513,283 individuals. Medicine. 2016;95:e4414.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96:2992–3003.CrossRefPubMed Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96:2992–3003.CrossRefPubMed
31.
Zurück zum Zitat Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology. 2010;138:877–885.CrossRefPubMed Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology. 2010;138:877–885.CrossRefPubMed
32.
Zurück zum Zitat Taylor DP, Stoddard GJ, Burt RW, et al. How well does family history predict who will get colorectal cancer? Implications for cancer screening and counseling. Genet Med. 2011;13:385–391.CrossRefPubMed Taylor DP, Stoddard GJ, Burt RW, et al. How well does family history predict who will get colorectal cancer? Implications for cancer screening and counseling. Genet Med. 2011;13:385–391.CrossRefPubMed
33.
Zurück zum Zitat Holme O, Bretthauer M, Eide TJ, et al. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut. 2015;64:929–936.CrossRefPubMed Holme O, Bretthauer M, Eide TJ, et al. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut. 2015;64:929–936.CrossRefPubMed
34.
Zurück zum Zitat Schoen RE, Weissfeld JL, Kuller LH. Are women with breast, endometrial, or ovarian cancer at increased risk for colorectal cancer? Am J Gastroenterol. 1994;89:835–842.PubMed Schoen RE, Weissfeld JL, Kuller LH. Are women with breast, endometrial, or ovarian cancer at increased risk for colorectal cancer? Am J Gastroenterol. 1994;89:835–842.PubMed
36.
Zurück zum Zitat Betes M, Munoz-Navas MA, Duque JM, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol. 2003;98:2648–2654.PubMed Betes M, Munoz-Navas MA, Duque JM, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol. 2003;98:2648–2654.PubMed
38.
Zurück zum Zitat Dunlop MG, Tenesa A, Farrington SM, et al. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. Gut. 2013;62:871–881.CrossRefPubMed Dunlop MG, Tenesa A, Farrington SM, et al. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. Gut. 2013;62:871–881.CrossRefPubMed
39.
Zurück zum Zitat Cheng JM, Chen Y, Wang XL, et al. Meta-analysis of prospective cohort studies of cigarette smoking and the incidence of colon and rectal cancers. Eur J Cancer Prev. 2015;24:6–15.CrossRefPubMed Cheng JM, Chen Y, Wang XL, et al. Meta-analysis of prospective cohort studies of cigarette smoking and the incidence of colon and rectal cancers. Eur J Cancer Prev. 2015;24:6–15.CrossRefPubMed
40.
Zurück zum Zitat Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose–response meta-analysis of published studies. Ann Oncol. 2011;22:1958–1972.CrossRefPubMed Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose–response meta-analysis of published studies. Ann Oncol. 2011;22:1958–1972.CrossRefPubMed
41.
Zurück zum Zitat Robsahm TE, Aagnes B, Hjartaker A, Langseth H, Bray FI, Larsen IK. Body mass index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-analysis of cohort studies. Eur J Cancer Prev. 2013;22:492–505.CrossRefPubMed Robsahm TE, Aagnes B, Hjartaker A, Langseth H, Bray FI, Larsen IK. Body mass index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-analysis of cohort studies. Eur J Cancer Prev. 2013;22:492–505.CrossRefPubMed
42.
Zurück zum Zitat Murphy N, Norat T, Ferrari P, et al. Dietary fibre intake and risks of cancers of the colon and rectum in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS ONE. 2012;7:e39361.CrossRefPubMedPubMedCentral Murphy N, Norat T, Ferrari P, et al. Dietary fibre intake and risks of cancers of the colon and rectum in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS ONE. 2012;7:e39361.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Pham NM, Mizoue T, Tanaka K, et al. Meat consumption and colorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44:641–650.CrossRefPubMed Pham NM, Mizoue T, Tanaka K, et al. Meat consumption and colorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44:641–650.CrossRefPubMed
44.
Zurück zum Zitat van Dam L, Kuipers EJ, Steyerberg EW, van Leerdam ME, de Beaufort ID. The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategies? Lancet Oncol. 2013;14:e38–e46.CrossRefPubMed van Dam L, Kuipers EJ, Steyerberg EW, van Leerdam ME, de Beaufort ID. The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategies? Lancet Oncol. 2013;14:e38–e46.CrossRefPubMed
45.
Zurück zum Zitat Seeff LC, DeGroff A, Joseph DA, et al. Moving forward: using the experience of the CDCs’ colorectal cancer screening demonstration program to guide future colorectal cancer programming efforts. Cancer. 2013;119:2940–2946.CrossRefPubMed Seeff LC, DeGroff A, Joseph DA, et al. Moving forward: using the experience of the CDCs’ colorectal cancer screening demonstration program to guide future colorectal cancer programming efforts. Cancer. 2013;119:2940–2946.CrossRefPubMed
Metadaten
Titel
Comparative Evaluation of Preliminary Screening Methods for Colorectal Cancer in a Mass Program
verfasst von
Ding Ye
Qiuchi Huang
Qilong Li
Xiyi Jiang
Mayila Mamat
Mengling Tang
Jianbing Wang
Kun Chen
Publikationsdatum
20.06.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 9/2017
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4648-1

Weitere Artikel der Ausgabe 9/2017

Digestive Diseases and Sciences 9/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.